Minerval
Sourceunknowntext stored

Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial

Author not recordedDate not recordedOriginal︎ ↗Archived copy

Claims1
ExaminationsNone
Text167 sections
VersionsOne known
CopiesNone recorded
CorrectionsNone recorded
Facts checked Nov 9, 2026
ReachNo copies recorded
StructureIn 1 claim's map0 sources downstream across 1 claim
EvidenceNot yet read
ReviewsNot reviewed

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text41 passages · 1 marked

No examination yetMarked passage
News0 passages
Watch Expert Conversations Shows & Podcasts News & Analysis0 passages
Conferences0 passages
Conference Coverage Conference Listing0 passages
Partners0 passages
More0 passages
CME/CE0 passages
Resources0 passages
Digital Supplements Interactive Tools Live Events Press Release Publications Sponsored0 passages
Advisory Board0 passages
Subscribe0 passages
Scout0 passages
My Account0 passages
Scout News0 passages
Watch0 passages
Conferences0 passages
Partners0 passages
CME/CE0 passages
Resources0 passages
Advisory Board0 passages
Subscribe0 passages
Allergy Seasonal Allergy0 passages
Food Allergy0 passages
Anaphylaxis0 passages
Biosimilars0 passages
Cardiology Dyslipidemia0 passages
Arrhythmia0 passages
Cardiomyopathy0 passages
Structural Heart Disease0 passages
Atherosclerotic Cardiovascular Disease0 passages
Heart Failure0 passages
Hypertension0 passages
Stroke0 passages
Dermatology Alopecia0 passages
Vitiligo0 passages
Hidradenitis Suppurativa0 passages
Acne0 passages
Atopic Dermatitis0 passages
Urticaria0 passages
Plaque Psoriasis0 passages
Endocrinology Type 2 Diabetes0 passages
Type 1 Diabetes0 passages
Polycystic Ovary Syndrome0 passages
Hormonal Disorders0 passages
Thyroid Disorders0 passages
FDA News0 passages
Family Medicine Influenza0 passages
Vaccination0 passages
Gastroenterology Exocrine Pancreatic Insufficiency0 passages
Inflammatory Bowel Disease0 passages
Eosinophilic Esophagitis0 passages
C Difficile Infection1 passage
Irritable Bowel Syndrome0 passages
Peptic Ulcer0 passages
Ulcerative Colitis0 passages
Geriatrics Dementia and Alzheimer Disease0 passages
Parkinson Disease0 passages
Hematology Paroxysmal Nocturnal Hemoglobinuria0 passages
Anemia0 passages
Sickle Cell0 passages
Hepatology Alpha-1 antitrypsin deficiency0 passages
Hepatitis B0 passages
Cholangitis0 passages
MASH / MASLD0 passages
Hepatitis C0 passages
Hospital Medicine0 passages
Infectious Disease COVID-190 passages
HIV/AIDS0 passages
Internal Medicine0 passages
Nephrology C3 Glomerulopathy0 passages
IgA Nephropathy0 passages
Focal Segmental Glomerulosclerosis0 passages
Chronic Kidney Disease0 passages
Neurology Epilepsy0 passages
Migraine0 passages
Tardive Dyskinesia0 passages
Traumatic Brain Injury0 passages
Obesity Management0 passages
Ophthalmology Geographic Atrophy0 passages
Age-Related Macular Degeneration0 passages
Diabetic Macular Edema0 passages
Uveitis0 passages
Pain Acute Pain0 passages
Chronic Pain0 passages
Multiple Sclerosis0 passages
Neuropathic Pain0 passages
Pediatrics0 passages
Psychiatry PTSD0 passages
Addiction0 passages
ADHD0 passages
Bipolar Disorder0 passages
Major Depressive Disorder0 passages
Schizophrenia0 passages
Pulmonology Lung Cancer0 passages
Pulmonary Fibrosis0 passages
Asthma0 passages
COPD0 passages
RDR Alert® Vasculitis0 passages
Amyloidosis0 passages
Huntington Disease0 passages
Lysosomal Storage Disorders0 passages
Rheumatology0 passages
Sleep Obstructive Sleep Apnea0 passages
Insomnia0 passages
Surgery0 passages
Women's Health0 passages
Choose Specialty Spotlight - FDA News |0 passages
This Year In Medicine 20250 passages
Advertisement0 passages
News | Articles | July 31, 20260 passages
Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial0 passages
Author(s) Patrick Campbell0 passages
Fact checked by: Ryan Livingston0 passages
Listen 0:00 / 0:000 passages
Key Takeaways5 passages
SHOW MORE0 passages
Advertisement4 passages
ZEUS trial design and primary results0 passages
Frequently Asked Questions6 passages · 1 marked

The primary endpoint was time to first occurrence of 3-point MACE, analyzed by Cox regression in the full analysis set. Ziltivekimab showed no reduction in MACE risk compared with placebo (HR, 0.99; 95% CI, 0.88-1.11). 1 The result held despite ziltivekimab producing the anticipated pharmacodynamic effect on the IL-6 pathway, according to Novo Nordisk, which noted expected reductions in free IL-6 and hsCRP consistent with target engagement. The lack of separation on the primary endpoint indicates inflammation reduction via IL-6 inhibition did not translate into a measurable cardiovascular benefit in this population.

The IL-6 inhibitor ziltivekimab did not reduce cardiovascular events in the ZEUS trialVerified

Not yet read by this claim’s Steward.

Ziltivekimab safety profile in ZEUS3 passages
References2 references
Advertisement0 passages
Nephrology1 passage
Cardiology1 passage
Clinical1 passage
Chronic Kidney Disease1 passage
Atherosclerotic Cardiovascular Disease0 passages
Related to this article0 passages
View more2 passages
Read more2 passages
Read more0 passages
November 7th, 2026 Ez-PAVE: Initial Statin-Ezetimibe Combination No Better than Statins Alone1 passage
Read more0 passages
November 7th, 2026 STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD1 passage
Read more2 passages
Read more2 passages
Read more2 passages
Read more0 passages
November 9th, 2026 Asundexian Receives FDA Approval for Secondary Stroke Prevention1 passage
Read more0 passages
Previous slide Next slide0 passages
Advertisement0 passages
Advertisement0 passages
Trending on HCPLive0 passages
10 passages
Zabopegdutide Improves Fibrosis, MASH Resolution at 48 Weeks0 passages
20 passages
Asundexian Receives FDA Approval for Secondary Stroke Prevention0 passages
30 passages
RNA Editing With WVE-006 Restores Functional AAT, Cuts Z-AAT in AATD0 passages
40 passages
Efinopegdutide Improves MASH Resolution, Fibrosis in Phase 2b Trial0 passages
50 passages
Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials0 passages
About Us0 passages
Advertise0 passages
Editorial0 passages
Contact Us0 passages
Do Not Sell My Information0 passages
Privacy0 passages
Terms & Conditions0 passages
Your Privacy Choices0 passages
Contact Info3 passages
Home0 passages
About Us0 passages
News0 passages
Contact Us0 passages

Lineage across 1 claim

Draws on · none recorded
This source
Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial
in 1 claim's map
Drawn on by · none recorded

Record

Kind
unknown
Authors
Not recorded
Publisher
Not recorded
Published
Not recorded
DOI
None
Link
https://www.hcplive.com/view/ziltivekimab-fails-to-reduce-mace-risk-in-phase-3-zeus-trial
Archived copy
https://web.archive.org/web/20261005110143/https://www.hcplive.com/view/ziltivekimab-fails-to-reduce-mace-risk-in-phase-3-zeus-trial
Stored text
10,970 characters, retrieved Aug 7, 2026 · 167 sections, 41 passages
Claims extracted
Not recorded
Versions
One known
Copies
None recorded
Corrections
None recorded
Facts checked
Nov 9, 2026

History 3

  1. Nov 11, 2026DividedSegmenter · Divided into 208 parts by its own structure
  2. Nov 11, 2026FactsFacts fetcher · Facts looked up
  3. Nov 11, 2026Entered the graphEntered the graph; copy stored
Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial · Minerval